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Background: Community-acquired pneumonia (CAP) is the third-leading infectious cause of death worldwide. The
standard treatment of CAP has not changed for the past fifty years and its mortality and morbidity remain high
despite adequate antimicrobial treatment. Systemic corticosteroids have anti-inflammatory effects and are therefore
discussed as adjunct treatment for CAP. Available studies show controversial results, and the question about benefits
and harms of adjunct corticosteroid therapy has not been conclusively resolved, particularly in the non-critical care
setting.
Methods/Design: This randomized multicenter study compares a treatment with 7 days of prednisone 50 mg with
placebo in adult patients hospitalized with CAP independent of severity. Patients are screened and enrolled within the
first 36 hours of presentation after written informed consent is obtained. The primary endpoint will be time to clinical
stability, which is assessed every 12 hours during hospitalization. Secondary endpoints will be, among others, all-cause
mortality within 30 and 180 days, ICU stay, duration of antibiotic treatment, disease activity scores, side effects and
complications, value of adrenal function testing and prognostic hormonal and inflammatory biomarkers to predict
outcome and treatment response to corticosteroids. Eight hundred included patients will provide an 85% power
for the intention-to-treat analysis of the primary endpoint.
Discussion: This largest to date double-blind placebo-controlled multicenter trial investigates the effect of adjunct
glucocorticoids in 800 patients with CAP requiring hospitalization. It aims to give conclusive answers about benefits
and risks of corticosteroid treatment in CAP. The inclusion of less severe CAP patients will be expected to lead to a
relatively low mortality rate and survival benefit might not be shown. However, our study has adequate power for
the clinically relevant endpoint of clinical stability. Due to discontinuing glucocorticoids without tapering after
seven days, we limit duration of glucocorticoid exposition, which may reduce possible side effects.
Trial registration: 7 September 2009 on ClinicalTrials.gov: NCT00973154.
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Respiratory infections, consisting mainly of pneumonia,
are the third leading infectious cause of death worldwide
[1]. Community-acquired pneumonia (CAP) is the main
cause for sepsis and septic shock, both of which carry a
high risk of long-term morbidity and mortality [2,3].
The standard treatment of CAP has not changed for
the past 50 years, and its mortality and morbidity has
remained high at 5 to 15% despite the availability of
broad-spectrum antibiotics [4]. Systemic corticosteroids
have anti-inflammatory effects [5,6] which, in CAP,
attenuate the systemic inflammatory process which may
have a detrimental impact [7] on the lung [8]. Therefore,
adjunct treatment with corticosteroids has been discussed
since the 1950s [9]. As early as 1955, favorable effects
of corticosteroids were reported in patients with pneumo-
coccal pneumonia [9]. A small-sized multicenter random-
ized trial showed a significant reduction in hospital
mortality in severe CAP with a seven-day continuous
infusion of hydrocortisone (240 mg/day), although this
study was not powered for mortality [10]. Another large,
but retrospective, single center study evaluated more than
300 patients and demonstrated in multivariable analysis
that use of corticosteroids was associated with a lower
mortality [11]. More recently, two randomized placebo-
controlled trials involving 200 to 300 patients showed
controversial results, one study showing no benefit of
adjunct prednisolone treatment and one study showing
a significant reduction in duration of hospital stay using
dexamethasone [6,12]. Three systematic reviews [13-15]
and one meta-analysis [16] concluded that the available
evidence suggests that administration of corticosteroids in
patients with CAP might be beneficial. However, a large
and adequately powered randomized trial is warranted to
support or refute this beneficial effect before recommen-
dations can be made with regard to use of corticosteroids
in the treatment of CAP. In addition, as the potential
harmful effects of corticosteroids in high-dose and
long-term treatment are well-known [17,18], special
attention has to be given to the side effects of cortico-
steroid treatment.
Methods
Objective and design
The objective of this trial is to evaluate whether treatment
with prednisone for seven days in patients with CAP as
compared to placebo reduces time to clinical stability.
This is a multicenter randomized placebo-controlled trial.
The local ethics committees: Ethikkommission beider Basel
EKBB (Reference Number 370/08), Ethikkommission der
Kantone Aargau und Solothurn (Reference Number 2011/
031), commission d’ethique Lausanne (Reference Number
116/10) and Ethikkommission Bern (Reference Number
193/11), as well as the Swiss Agency for TherapeuticProducts SWISSMEDIC (Reference Number 2009DR3227)
approved the study protocol after meeting imposed condi-
tions. This trial adheres to the declaration of Helsinki and
was registered at clinicaltrials.gov as NCT00973154 on 7
September 2009. The protocol follows the recommen-
dations of the SPIRIT initiative [19], and the trial results
will be reported according to the latest version of the
CONSORT statement [20].
Study setting and participants
All adult patients with CAP are screened and enrolled at
emergency departments or medical wards in seven tertiary
care hospitals of Switzerland within 24 hours; on week-
ends within 36 hours of hospitalization. Eligible patients
are asked for their informed consent and are then centrally
randomized to either 50 mg prednisone or to placebo,
taken orally for 7 days in a ratio of 1:1. If the patient is not
able to give informed consent at the time of hospitalization
due to severity of CAP, informed consent from next of
kin and an independent physician is obtained. In these
cases, informed consent from the patient himself has to
be obtained as soon as possible. Patient recruitment started
in December 2009 and is planned to be completed in April
2014.
Inclusion criteria are age of 18 years or older and
hospitalization with CAP defined by a new infiltrate on
chest radiograph and the presence of one or several of the
following acute respiratory signs or symptoms: cough, spu-
tum production, dyspnea, core body temperature ≥ 38.0°C,
auscultatory findings of abnormal breath sounds and rales
and leukocyte count > 10 or < 4 G/L [21].
Exclusion criteria are permanent inability for informed
consent, active intravenous drug abuse, acute burn injury,
gastrointestinal bleeding within the past three months,
known adrenal insufficiency, a condition requiring more
than 0.5 mg/kg/day prednisone equivalent, pregnancy or
breast feeding, and severe immunosuppression defined as
previously known infection with HIV and a CD4 cell count
below 350 G/L, immunosuppressive therapy after solid
organ transplantation, neutropenia < 500 G/L or a neutro-
phil count of 500 to 1,000 G/L with an expected decrease
to values < 500 G/L in patients under ongoing chemother-
apy, cystic fibrosis and active tuberculosis.
Randomization and blinding
Allocation of patients to either intervention in this
randomized placebo-controlled trial is concealed due
to a pre-specified computer-generated randomization
list which is kept centrally at the pharmacy of the main
study center. Randomization between the two arms are
1:1 with variable block sizes of 4 to 6 and are stratified
at the time of study entry by study center.
Generator and executor of randomization are separated.
Patients are randomly assigned to receive a prepared set
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nisone or placebo. The drugs are prepared prior to the ini-
tiation of the study and packed by the Pharmacology
Department, University Hospital, Basel, according to the
randomization list. The numbered study medications are
then delivered to the study team. By this method, study
team including data analysts, patients and treating physi-
cians will be blinded to group allocation. Unblinding will
be performed only upon request of a treating physician or
of the data safety and monitoring board (DSMB).
Study protocol
The study flow chart is shown in Figure 1. After informed
consent is obtained, baseline blood is drawn and a low-dose
adrenocorticotropic hormone (ACTH) test is performed
(measurement of basal cortisol followed by cortisol after
0.001 mg of tetracosactid (Synacthen®)). Study medication
is started after the ACTH test, and timing in relation to
start of antibiotics will be monitored. Patients are evalu-
ated for the primary endpoint of clinical stability every
12 hours during the hospitalization. All patients are being
treated according to current CAP guidelines [22,23].
Antibiotic therapy guided by an established procalcitonin
algorithm [24] is encouraged. The time of discharge is not
determined by the study investigators, but based on the
decision of the treating physician team.
Laboratory assessment
The blood samples drawn on days 1, 3, 5, 7 and at dis-
charge are immediately centrifuged and stored at −70°C
until further processing. All laboratories of the participat-
ing centers are internationally validated and standardized.
Cortisol is measured immediately. Routine laboratory tests
in both groups include procalcitonin, C-reactive protein
(CRP), white blood cell count, sputum and blood cul-
tures, nasal swab for virus multiplex PCR, Legionella
and pneumococcal antigen in urine. Other laboratory
markers as well as genetic markers will be measured in
batch analysis from stored serum or plasma samples, re-
spectively, after the study is terminated.
Data collection
Baseline data are collected by electronic case report
forms (eCRF) compliant to good clinical practice (GCP)
and contain date and time of randomization, birth date,
sex, medical history items (dyspnea at rest or after
having taken a flight of stairs, cough, smoking history
(pack-years) and status (pack per day), relevant co-
morbidities, degree of autonomy at home, clinical items
of pneumonia, pneumonia severity index (PSI), extent
of pneumonia, underlying chronic obstructive pulmonary
disease (COPD) as assessed by patient history and medical
documents.In both groups, hospitalized patients are reassessed
clinically every 12 hours (including vital signs) and blood
sampling on days 3, 5 and 7 including 4 measurements
of glucose levels on days 3, 5 and 7, respectively. Details
on dosing of all prescribed antimicrobials during the study
period are recorded. In hospitalized patients, hospital
discharge is recommended if oral intake is feasible, vital
signs are stable ≥ 24 hours, and no evidence of acute
serious co-morbidity that necessitates hospitalization
is found. A final blood collection is foreseen on the day
of discharge.
On days 1 and 5, the patient has to complete a short
questionnaire on respiratory symptoms.
Any additional diagnostic testing in patients in both
groups is at the full discretion of the treating physician.
Follow-up
Structured follow-up telephone interviews for secondary
outcomes after discharge are performed on days 30 and
180. In case the patient cannot be contacted or cannot
give sufficient information, the primary care physician is
interviewed.
Follow-up items include assessment of adverse events,
such as infections, recurrent pneumonia, re-hospitalization,
new diabetes or insulin dependence, new hypertension, and
the standardized questionnaire on respiratory symptoms
that was used on days 1 and 5.
Endpoints
Primary endpoint
Primary endpoint is time to clinical stability, which is
defined as follows: time (days) until stable vital signs
for ≥ 24 hours [21]:
Temperature ≤ 37.8°C without antipyretic agents, heart
rate/minute ≤ 100, spontaneous respiratory rate ≤ 24 per
minute, systolic blood pressure ≥ 90 mmHg (≥100 mmHg
for patients diagnosed with hypertension) without vaso-
pressor support, mental status back to level before CAP,
adequate oxygenation on room air of oxygen therapy
(PaO2 ≥ 60 mmHg or pulse oximetry ≥ 90%). For patients
with chronic hypoxemia or chronic oxygen therapy, PaO2
or pulse oximetry measurement must be back to baseline.
Nurses on the wards unaware of treatment allocation as-
sess clinical stability during hospitalization every 12 hours.
Secondary endpoints
We will consider the following secondary endpoints:
 All-cause mortality within 30 and 180 days
 ICU stay and time to transfer to ICU
 in ICU patients: time to discharge from ICU;
duration of vasopressor treatment; duration of
mechanical ventilation
 Time to effective hospital discharge (days)
Figure 1 Study flow chart.
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treatment (days)
 Disease activity scores. This will be evaluated by a
CAP specific disease activity score [25]. Number of
days with restriction from CAP, and daily function
and health state will be evaluated, all assessed at
baseline, at days 5, 30 and 180
 Side effects and adverse effects of corticosteroid
treatment (which are rate of hyperglycemia,
hypertension, weight gain, delirium, nosocomial
infections) as assessed by a validated questionnaire[26] as well as by blood glucose, weight and blood
pressure monitoring
 Incidence of CAP complications until days 30 and
180 (which are persistence of pneumonia, acute
respiratory distress syndrome (ARDS), empyema)
 Microbiological, clinical and/or radiological
recurrence within 30 and 180 days
 Time to earliest possible hospital discharge (days)
based on objective criteria (possible oral intake of
food, liquids and drugs, stable vital signs > 24 hours,
recovery from CAP-related worsening of mental
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co-morbidity that necessitates hospitalization. This
endpoint will minimize a potential bias due to extended
hospitalization for non-disease specific reasons (request
from patients or their relatives, lack of adequate home
care support, or possibility for transferral to nursing
home, lack of assurance about compliance with
treatment)
 Late failure (that is recurrence of signs and symptoms
of pneumonia after 72 hours of randomization after
an initially beneficial response to treatment) [12]
Subgroup analyses
We plan to explore treatment effects according to the
following parameters:
 Above versus below the median initial CRP and
maximal CRP (hypothesis: patients with higher CRP
benefit more from adjunct corticosteroid therapy)
 Age < 70 years versus > 70 years (hypothesis: patients
above 70 years benefit more, as older-aged patients
present with more severe CAP and have a higher
mortality [27]. So far, there is no age-related data on
adjunct glucocorticoid therapy, but in severe CAP
there is more evidence for benefit of glucocorticoid
therapy [16])
 Severity of CAP (low-risk group: PSI I to III versus
high-risk group: PSI IV to V (hypothesis: patients
with more severe CAP and supposedly more severe
inflammation benefit more)
 Microbiological subgroups with versus without
bacteremia (hypothesis: patients with bacteremia
benefit more)
 With versus without underlying COPD according to
the Global initiative for chronic Obstructive Lung
Disease (GOLD) classification (hypothesis: patients
with COPD benefit more)
 COPD patients with GOLD category I to II versus
III to IV (hypothesis: patients with GOLD category
III to IV benefit more)
Sample size considerations
This study is designed to show superiority of the steroid
group compared to placebo treatment. Our primary
hypothesis is that adjunct corticosteroid treatment in
patients with CAP will result in a reduced time to clinical
stability compared to placebo treatment. To estimate the
frequency of our primary endpoint, we used data of CAP
patients from our completed studies [24,28,29] which
were performed in the same study centers. Based on these
previous trials, we assumed a mortality rate of 10% in the
placebo group and 7.5% in the corticosteroid group over
14 days of follow-up with a proportion of 75% survivors
being clinically stable after 7 days in the corticosteroidgroup. Estimating a decrease in the risk of non-stability
after 1 week among survivors by 25% through adjunct
corticosteroids, a sample size of 800 patients followed
for at least 14 days after randomization will be needed
to achieve a statistical power of 85% and a sample size of
700 patients to achieve a statistical power of 80% (2-sided
type 1 error of 5% in both scenarios). We intend to recruit
800 study patients from December 2009 to April 2014.
Intention-to-treat and per-protocol population
Following the intention-to-treat principle, all patients
receiving at least one dose of study medication will be
included in the analysis with group allocation as ran-
domized; patients violating inclusion criteria or meeting
exclusion criteria due to information that was not avail-
able at study entry will be excluded post randomization in
a blinded manner [30]. Criteria for exclusion of patients
from the per-protocol analysis are, in addition, withdrawal
of informed consent or non-compliance with study medi-
cation or the concomitant procedures. Therefore, patients
stopping or pausing the study medication at any time
point, be it due to corticosteroid contraindications or due
to active indication for glucocorticoid treatment, will not
be considered in the per-protocol analysis. A patient will
not be followed up if he withdraws informed consent for
all study measures; in all other cases, follow-up will be
performed as planned.
Statistical analysis
We will enter all relevant clinical and laboratory data
obtained by interview, clinical tests, and reviewing of the
medical records into an online database. Statistical Ana-
lysis System (SAS® Institute, Cary, NC, USA) and R for
Windows (R Foundation for Statistical Computing, www.
r-project.org) and STATA 9.2 (Stata Corp, College Station,
TX, USA) will be used for data analysis.
The primary analysis population is the full analysis set
which includes the intention-to-treat population. Every
effort will be made to minimize the number of losses to
follow-up by recording phone numbers before discharge,
thereafter by repetitive follow-up calls by home or cell
phone contact, or alternatively by contacting the primary
care physician. For the primary outcome of time to clinical
stability, we consider losses to follow-up in this sample of
hospitalized patients as unlikely. If losses to follow-up do
occur, patients will be censored at time of last assessment
for clinical stability. A secondary analysis population, the
per-protocol population, will exclude patients not treated
according to the protocol (that is protocol violators). For
the primary endpoint, we will calculate an unadjusted
hazard ratio and 95% confidence interval by means of a
Cox proportional hazards model. The primary object-
ive is to show superiority of the corticosteroid group at
a 2-sided 5% alpha-level with 85% power following the
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primary analysis will be repeated on the per-protocol
patient population. As a further sensitivity analysis, a
multivariable Cox proportional hazards model will be
fitted with treatment group, patient age, and PSI scores
as independent variables. This model will adjust the
treatment effect for the potentially important confounders
age and PSI score. Moreover, we plan to investigate
whether the treatment effect varies among different
degrees of severity of CAP (low-risk group: PSI I to III,
and high-risk group: PSI IV to V), between patients
with and without underlying COPD, and between
bacteremic versus non-bacteremic patients. COPD will
be defined by post-bronchodilator spirometric criteria,
according to the GOLD guidelines [31], as a FEV1/FVC
ratio below 70% and the severity categorized according to
the GOLD criteria. In patients with a clinical history of
COPD or smoking, lung function at the time of inclusion
will not be mandatory. We will conduct the pre-specified
subgroup analyses by including appropriate interaction
terms in the above described multivariable Cox propor-
tional hazards model.
Complete case analyses will be used for secondary
endpoints. For all secondary endpoints, we will calculate
unadjusted and adjusted estimates of the effect size and
corresponding 95% confidence intervals using linear, logis-
tic, or Cox proportional hazards regression (as appropri-
ate). Figure 2 shows the CONSORT diagram of the trial.Figure 2 CONSORT diagram of the trial.Study organization
All adverse events of category III or more according to
Common Terminology Criteria for Adverse Events v4.0
[32] are recorded. Adverse events will be monitored for
every subject participating in the study and attributed to
the study medication and reported to the respective au-
thorities according to law if necessary.
The trial is supervised by an independent and blinded
DSMB that is not involved in the design and conduct of the
trial, and has no affiliation with the sponsor. The DSMB is
comprised of experts from different disciplines and super-
vises the recruitment of patients, patient flow and patient
interviews. The board has access to the randomization code
in case of need. In case of serious problems or adverse events
that may occur during the trial, the board will review the pre-
planned interim analysis and inform the principle investiga-
tors whether the trial may be continued or has to be stopped
early or it may require modifications of the protocol.
A blinded safety interim analysis was performed after
50% of patients had completed the 180 day follow-up.
The DSMB recommended continuation of the study
without changes to the protocol.
In accordance with applicable regulations and GCP, a
study monitor is periodically controlling study procedures.
Planned subprojects
We will use data collected during this trial for further
analyses investigating the following topics:
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(ACTH test)
 Prognostic value of hormonal and inflammatory
biomarkers (for example, total and free cortisol
levels, copeptin, dehydroepiandrosterone (DHEA)
as well as the ratio of cortisol to DHEA [33]) in a
further attempt to identify those patients who
benefit most from corticosteroid treatment
 Effect of corticosteroid treatment on inflammatory
markers
 Prognostic value of hormonal biomarkers for risk
assessment in patients with CAP
 Microbiological etiology of pneumonia (bacterial
testing in blood, sputum and urine, viral multiplex
PCR from nasal swabs)
 Predictability of patients and doctors whether the
study medication was prednisone or placebo
Discussion
Even with the prescription of newer and more potent
antimicrobial agents, mortality due to CAP has remained
relatively constant over time. Corticosteroids have been
proved to block several arms of the inflammatory cascade.
Available evidence so far, derived from a few, mainly small
randomized controlled trials, suggests that corticosteroid
treatment might be beneficial in terms of survival in
patients with CAP [6,9,10,34-36].
Most studies showing a beneficial effect of corticoste-
roids in patients with CAP only included severe pneumo-
nia, as defined with a PSI class IV and V [11,34,37,38]. In
these patients, reviews and meta-analyses [13-16] pointed
to a possible benefit of corticosteroids on either length of
stay or mortality without evidence of more complications.
However, insufficient data on non-severe CAP are avail-
able. Recently, two randomized double-blind controlled
trials including 200 to 300 patients with all severities of
CAP found controversial results: the first study using
40 mg of prednisolone for seven days showed no effect on
time to clinical stability, with a higher rate of late failure in
the corticosteroid group, defined by recurrence of signs
and symptoms of pneumonia after 72 hours of admission
after an initially beneficial response to treatment [12]. The
second study using 4 days of 5 mg of dexamethasone
intravenously showed a significantly shorter duration of
hospital stay in patients treated with corticosteroids [6,12].
In view of these controversial findings, a large prospective
and adequately powered trial should conclusively deter-
mine the risks and benefits of adding corticosteroids to
the treatment of patients with CAP.
In the current trial, we will include all severity levels
of CAP (PSI I to V) requiring hospitalization. This will
lead to a lower mortality rate than observed in previous
studies only including severe CAP patients, and our
study will not be powered to show a survival benefit. Wetherefore chose as primary endpoint time to clinical sta-
bility, which is a less stringent but still clinically relevant
endpoint. By reducing the time to clinical stability and
consecutively also length of stay (LOS), nosocomial
complications like infections, thrombembolic events,
worsening of pre-existing frailty or delirium may be
prevented. This leads to better allocation of resources
at the hospital and to a marked reduction of costs [39].
While Meijvis et al. looked at LOS [6], our primary
endpoint will be time to clinical stability, as defined by
IDSA/ATS guidelines [22]. As we have previously observed,
LOS itself in community-acquired pneumonia may be
confounded and prolonged by medical or organizational
problems unrelated to CAP [39-41]. We believe that by
measuring time to clinical stability, we will be looking at a
clinically relevant parameter, as patients are able to switch
to oral antibiotics and ready for discharge once they reach
stability.
Inclusion of all patients with CAP will increase the
generalizability of the findings and allow retrospective
evaluation in exploratory analyses as to which patients
indeed profited most from corticosteroid treatment.
In our study, we administer an oral dose of 50 mg
prednisone for 7 days without tapering. We opted for an
oral formula, as the bioavailability of oral prednisone is
excellent, it may be ground and is therefore applicable in
patients not able to swallow, such as in patients on
mechanical ventilation or older-aged patients. Further-
more, by choosing a uniform application formula, further
bias, like the ability to blind and to secure provision of
blinded study medication 24 hours on 7 days per week,
was prevented.
The ideal choice and duration of corticosteroid treatment
in critically ill patients and patients with CAP is currently
disputed. Hydrocortisone is the natural corticosteroid and
was used in some studies in critically ill patients, partly to-
gether with a mineralocorticoid [42]. Most patients in our
study, however, will not suffer from critical illness and will
be hospitalized outside the ICU on the wards where oral
intake of treatment is preferred. Since hydrocortisone is
only available in 10 mg tablets, patients would have to
take 20 tablets a day, which does not appear feasible.
Methylprednisolone and prednisolone have also been
used in some studies including patients with CAP and
ARDS [10,12,43,44], putting it forward as an alternative
formulation for our study, as adequate oral formulations
are available. Prednisolone is the pharmacologically active
metabolite of prednisone, which was used in this study;
both are used interchangeably except in patients with se-
vere liver insufficiency, where prednisolone is preferred.
Dexamethasone was not recommended by guidelines for
use in septic shock and ARDS at the time of study design
[37]. However, a recent study showed a reduced length of
hospital stay in CAP patients treated with dexamethasone
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possible type of corticosteroid in patients with CAP.
The additional use of fludrocortisone as in the study by
Annane et al. [42] is currently considered optional [37].
Furthermore, the optimal duration of glucocorticoid
treatment and mode of discontinuing (tapering or not)
is not known and heavily disputed [45,46].
In high-dose glucocorticoid studies, which used as high
as 1 to 3 g hydrocortisone per day, short-term complica-
tions, such as co- and re-infections, led to excess mortality
[47,48]. In so-called low- or physiological-dose glucocortic-
oid studies with 100 to 300 mg hydrocortisone-equivalent
per day, the main adverse effects included hyperglycemia
[6] and rebound pneumonia [12]. Although confusion,
co-infection and gastrointestinal side effects were reported
in association with glucocorticoid treatment, the incidence
was not significantly higher in the steroid group [16].
While some authors advise five days of glucocorticoid
treatment in critically ill patients without tapering [49-51],
others recommend tapering of glucocorticoids to avoid
a rebound of inflammatory markers with consecutive re-
bound pneumonia [37,45,46,52]. However, it has been
shown that glucocorticoids given > seven days lead to a
worse clinical course measured by length of stay, clinical
stability and mechanical ventilation, and more systemic
complications when looking at shock and cardiac
arrhythmia [53]. From COPD studies, there is evidence
that stopping glucocorticoids without tapering is safe
without an increased recurrence rate [54]. For these
reasons, we decided against tapering of the gluco-
corticoid dose in order not to prolong glucocorticoid
exposure.
In conclusion, this current large and adequately pow-
ered randomized trial will determine the risks and benefits
of adding 50 mg of prednisone for 7 days to the treatment
of hospitalized patients with CAP. Our hypothesis is that
corticosteroid treatment will result in a reduced time to
clinical stability in CAP compared to placebo treatment.
Study limitations
The results of this trial may only be valid for the specific
type, dose and duration of glucocorticoid studied.
This study is powered for clinical stability, but not for
mortality; at least 4,000 patients would be needed to be
powered to detect a clinically relevant difference in
mortality.
Furthermore, we also included lower severity CAP pa-
tients, which might weaken the effect of glucocorticoids.
A conclusion for ICU patients might not be possible as
the number of these patients included will be low. There
is an ongoing ICU multicenter study (clinicaltrials.gov
number NCT01448109) aiming for the goal of 4,000
patients that will hopefully answer this question for ICU
patients with CAP.Trial status
Recruiting. On 15 October 2013, 670 patients had been
enrolled in the study.
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